Allopurinol TreatmenT And oxypurinol Concentrations in gouty patients: Knowing the therapeutic window.
Phase 4
Completed
- Conditions
- Aandoening van het bewegingsapparaatgout
- Registration Number
- NL-OMON33306
- Lead Sponsor
- Medisch Centrum Leeuwarden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
1. Confirmed gout with urate crystals or tophi
2. First treatment with allopurinol
3. Filled and signed informed consent
Exclusion Criteria
1. Patients younger than 18 years and pregnant women
2. Patients with eGFR <20 ml/min
3. Patients using azathioprine, mercaptopurine or cyclofosfamide
4. patients with elevated liverenzymes, defined as more than twice baseline ASAT or ALAT values
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- association between oxypurinol concentration and the chance on succesfull<br /><br>treatment of gout (defined as<br /><br>reaching urate concentrations of <0,30 mmol/l)</p><br>
- Secondary Outcome Measures
Name Time Method <p>- association between oxypurinol concentration and the risk of getting adverse<br /><br>drug reactions<br /><br>- association between oxypurinol concentration and the chance on succesfull<br /><br>treatment of gout (defined as<br /><br>reaching urate concentrations of <0,36 mmol/l)<br /><br>- percentage of patients succesfully treated with the proposed dosage nomogram<br /><br>- the role of genetic variations on the occurence of adverse reactions</p><br>